Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Hahn

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Induction of multiple HIV-1 neutralizing B Cell Precursors in HumansChen-Hao Yeh, Stephen R Walsh, Ruth Parsons, et al.
Science Translational Medicine|July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK Rachael Parks, Zoe Moodie, Mary A Allen, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.
The Journal of Experimental Medicine|September 5, 2024
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodiesWilliam O Hahn, K Rachael Parks, Mingchao Shen, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Induction of multiple HIV-1 neutralizing B Cell Precursors in HumansChen-Hao Yeh, Stephen R Walsh, Ruth Parsons, et al.
Science Translational Medicine|July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK Rachael Parks, Zoe Moodie, Mary A Allen, et al.
Pageof 4